Indications of Everolimus

Hormone Receptor-Positive, HER2-Negative Breast Cancer: Indicated for postmenopausal women in combination with exemestane for the treatment of advanced patients whose disease has progressed following letrozole or anastrozole therapy.

Neuroendocrine Tumors (NETs):

Indicated for adults with progressive pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic.

Indicated for adults with progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or pulmonary origin that are unresectable, locally advanced, or metastatic.

Usage Restriction: Not indicated for the treatment of functional carcinoid tumors.

Renal Cell Carcinoma (RCC): Indicated for adults with advanced renal cell carcinoma following failure of sunitinib or sorafenib therapy.

TSC-Associated Renal Angiomyolipoma: Indicated for adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) who do not require immediate surgery.

TSC-Associated Subependymal Giant Cell Astrocytoma (SEGA): Indicated for adults and pediatric patients aged 1 year and older with tuberous sclerosis complex (TSC) for the treatment of SEGA that requires therapeutic intervention but cannot be curatively resected surgically.

TSC-Associated Partial Seizures: Indicated for adults and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC) as adjunctive therapy for partial seizures.

FDA，2022.02